医学
急性冠脉综合征
他汀类
心肌梗塞
随机对照试验
置信区间
优势比
物理疗法
内科学
临床终点
初级保健
冠状动脉监护室
析因分析
急诊医学
医疗保健
急症护理
可能性
冲程(发动机)
作者
Nihar R. Desai,Kirk U. Knowlton,Jeffrey L. Anderson,Joseph Brent Muhlestein,Kelly Kleeman,Samiha Sarwat,Mary Ann Ramirez,Cindy Lee Grines,Wael S. Abo-Auda,Alan S. Brown
标识
DOI:10.1016/j.jacl.2026.05.162
摘要
CVD Prevention – Primary and Secondary Guideline-directed low-density lipoprotein cholesterol (LDL-C) goals are not met by many patients with recent acute coronary syndrome (ACS). The 330-day, phase 3b, open-label VICTORION-INCEPTION (NCT04873934) trial was the first to evaluate LDL-C lowering and goal attainment with inclisiran in participants with recent ACS in a setting designed to mimic real-world practice. Participants (discharged from hospitalization for ACS ≤5 weeks before screening with LDL-C ≥70 mg/dL, or non–high-density lipoprotein cholesterol ≥100 mg/dL, receiving statin therapy or with statin intolerance) were randomized 1:1 to inclisiran (inclisiran sodium 300 mg [284 mg inclisiran equivalent] on Days 0, 90, and 270) + usual care or to usual care. We present analyses of LDL-C <70 mg/dL (coprimary endpoint) and <55 mg/dL (secondary endpoint) goal attainment at Day 330 by predefined and post hoc subgroups. Sustained goal attainment between time points was assessed post hoc. Of 400 randomized participants, 29.0% were female, 15.3% were non-White or multiple races, and 14.3% were Hispanic or Latine. Most participants had no history of statin intolerance (87.8%), and 82.0% were receiving high-intensity statin at baseline. The most frequent index ACS event was non–ST-segment elevation myocardial infarction (53.5%). Overall, significantly more participants receiving inclisiran + usual care achieved LDL-C goals at Day 90 vs usual care (<70 mg/dL: 74.6% vs 26.6%, odds ratio [OR]: 10.84 [97.5% confidence interval {CI}: 6.13-19.16], P <0.001; <55 mg/dL: 63.2% vs 8.5%, OR: 26.58 [95% CI: 14.14-49.98], P <0.001). Of participants at goal at Day 90, goal attainment was sustained to Day 330 in more participants receiving inclisiran + usual care vs usual care (<70 mg/dL: 75.3% vs 62.3%; <55 mg/dL: 68.5% vs 58.8%; Figure 1 ). Across subgroups, the proportion of participants with LDL-C <70 mg/dL or <55 mg/dL at Day 330 was consistently greater with inclisiran + usual care vs usual care ( Figure 2 ). In this analysis of participants with recent ACS in VICTORION-INCEPTION, treatment with inclisiran + usual care resulted in rapid and sustained LDL-C goal attainment compared with usual care. These findings highlight the potential role of inclisiran in enabling guideline-directed LDL-C goal attainment among patients with recent ACS.
科研通智能强力驱动
Strongly Powered by AbleSci AI